iShares Genomics Immunology and Healthcare ETF Rating $34.91 0.00 (0.00%) As of 07/2/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock iShares Genomics Immunology and Healthcare ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IDNA Aggregate RatingModerate Buy 2.58Holdings in IDNA have an aggregate rating of Moderate Buy based on 278 analyst ratings issued in the past year covering 17 companies (55.3% of the portfolio).IDNA Aggregate Price Target$34.91High Prediction$34.91Average Prediction$34.91Low Prediction$34.91Holdings in IDNA have an aggregate price target of $34.91 and a range of $34.91 to $34.91 covering 17 companies (55.3% of the portfolio).IDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Genomics Immunology and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 17 IDNA Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.75%MRNAModerna$79.761.1686 of 5 stars1.83$37.13 -53.4%18Trending NewsGap Down4.67%TWSTTwist Bioscience$99.241.6781 of 5 stars2.80$79.30 -20.1%10Positive NewsGap Up4.21%RVMDRevolution Medicines$189.241.9029 of 5 stars3.00$135.39 -28.5%22News CoverageAnalyst ForecastInsider Trade3.96%VRTXVertex Pharmaceuticals$528.043.5684 of 5 stars2.84$555.91 5.3%25Analyst DowngradeInsider TradeGap Down3.88%BNTXBioNTech$97.543.6109 of 5 stars2.74$129.56 32.8%19News CoverageGap Down3.84%INCYIncyte$116.863.9941 of 5 stars2.36$107.85 -7.7%22Options VolumeGap Down3.70%EXELExelixis$55.852.2898 of 5 stars2.35$47.60 -14.8%20Analyst ForecastOptions VolumeGap Down3.66%REGNRegeneron Pharmaceuticals$654.274.8574 of 5 stars2.73$792.65 21.2%26Positive NewsAnalyst DowngradeGap Down3.63%MRKMerck & Co., Inc.$129.34-0.2%4.474 of 5 stars2.70$131.83 1.9%20Positive NewsAnalyst ForecastAnalyst RevisionGap Down3.39%IDYAIDEAYA Biosciences$37.653.1416 of 5 stars2.82$50.69 34.6%173.23%IBRXImmunityBio$9.442.8015 of 5 stars2.71$14.20 50.4%7News CoverageInsider TradeGap Down2.71%RCUSArcus Biosciences$30.42+0.3%2.1913 of 5 stars2.58$35.10 15.4%122.52%CAICaris Life Sciences$18.304.096 of 5 stars2.45$27.56 50.6%11Analyst ForecastGap Up1.88%IOVAIovance Biotherapeutics$4.312.1298 of 5 stars2.30$8.43 95.6%10Analyst RevisionGap Down1.85%CRSPCRISPR Therapeutics$60.082.1276 of 5 stars2.58$67.78 12.8%19News CoverageAnalyst DowngradeOptions Volume1.70%NUVBNuvation Bio$5.69-0.3%4.0321 of 5 stars2.55$12.50 119.9%11Gap Down1.67%NVAXNovavax$9.741.8655 of 5 stars2.22$13.00 33.5%9 This page (NYSEARCA:IDNA) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Genomics Immunology and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Genomics Immunology and Healthcare ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
